氯化锶联合黛力新治疗恶性肿瘤骨转移疼痛的临床疗效

目的:观察氯化锶(89SrCl2)联合黛力新治疗恶性肿瘤骨转移疼痛患者的临床疗效，并对该联合治疗手段进行可行性分析。方法:选取符合条件的恶性肿瘤骨转移疼痛患者120例，随机分为联合治疗组与对照组，联合治疗组采用89SrCl2联合黛力新治疗，对照组单用89SrCl2治疗，比较两组患者的疼痛反应情况、骨转移灶疗效、患者的心理状态、生活质量评分以及不良反应发生率。结果:联合治疗组患者治疗后骨痛缓解总有效率为85.00%，高于对照组(68.33%)，差异有统计学意义(P=0.031)。两组心理状态比较，联合治疗组治疗后1、2、3个月HAM-D及HAM-A评分均低于对照组，焦虑抑郁状态改善明显，差异有统计学意义(均P<0.05)。治疗后两组生活质量情况比较，联合治疗组的整体健康状况得分及功能量表中情绪功能与认知功能得分高于对照组，差异有统计学意义(均P<0.05)，症状量表中疲乏、疼痛评分与单项测试量表中睡眠障碍评分低于对照组，症状改善明显，差异有统计学意义(均P<0.05)。两组骨转移灶治疗效果及不良反应发生率无统计学差异(均P>0.05)。结论:在常规应用氯化锶抗骨转移治疗同时联合黛力新抗抑郁治疗可明显缓解恶性肿瘤骨转移疼痛患者的焦虑抑郁状态，改善病人的生存质量，并对缓解癌性骨痛具有增益价值，且不良反应轻微，安全性高，是肿瘤综合治疗的重要补充，值得临床推广应用。

Clinical evaluation of 89SrCl2 combined with Deanxit in the treatment of patients with pain from bone metastasis of malignant tumor

Objective:To observe the clinical efficacy of 89SrCl2 combined with Deanxit in the treatment of patients with pain from bone metastasis of malignant tumor and to analyze the feasibility of the combined treatment.Methods:120 patients with malignant tumor bone metastasis were selected and randomly divided into the combination treatment group and the control group.The combination treatment group was treated with 89SrCl2 combined with Deanxit，and the control group was treated with 89SrCl2 alone.The analgesic effect，the effect of bone metastases，psychological scale,quality of life scores and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of bone pain relief after treatment in the combination treatment group was 85.00%，higher than that in the control group (68.33%)，and the difference was statistically significant (P=0.031).Compared with the control group，the HAM-D and HAM-A scores in the combination treatment group were lower than those in the control group at 1，2 and 3 months after treatment，with significant improvement in anxiety and depression status，and the differences were statistically significant (all P<0.05).The quality of life of the two groups was compared.After treatment，the scores of global health status，the scores of emotional and cognitive functioning in the functional scales of the combination treatment group were higher than those of the control group，and the differences were statistically significant (all P<0.05).The fatigue and pain scores in the symptom scales and the insomnia score in the single test scales of the combined group were lower than those in the control group，with significant improvement in symptoms，and the differences were statistically significant (all P<0.05).There was no significant difference in the effect of bone metastases and the incidence of adverse reactions between the two groups (all P>0.05).Conclusion:89SrCl2 with Deanxit can significantly alleviate the anxiety and depression of patients with pain from bone metastasis of malignant tumors，improve the quality of life，and has a gain value in alleviating bone pain caused by cancer，with mild adverse reactions and high safety.It is an important supplement to the comprehensive treatment of tumors and is worthy of clinical application.